Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
J Obstet Gynaecol Res ; 47(11): 3979-3989, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34396646

ABSTRACT

AIM: The purpose of this study was to investigate whether the Ki67 values were associated with survival for predicting prognosis in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy (NACT). METHODS: Among 17 patients treated with NACT, 13 patients were available for tissue samples from matched pre- and post-therapy tissues. Ki67 scores were transformed to a logarithmic scale for the statistical analyses. The optimal cutoff values of the log-phase Ki67 were assessed by receiver operating characteristic (ROC) analysis. Kaplan-Meier analysis, the log-rank test, and Cox regression analysis were carried out to analyze survival. RESULTS: The Ki67-decrease and post-NACT Ki67 were the independent factors associated with relapse-free survival (RFS) (p < 0.001 and p = 0.003). No association was observed on overall survival. The optimal cutoff values for the Ki67-decrease and the post-NACT Ki67 were 6.67% and 5.46 based on ROC where the area under ROC curves (AUC) were 1.00 (p < 0.001) with the 100% sensitivity and specificity. The median RFS was 537 days in patients showing Ki67-decrease >6.66% or post-NACT Ki67 level <5.46, while it was 224 days in those with Ki67 decrease ≤6.66% or post-NACT Ki67 level ≥5.46 (p = 0.001). CONCLUSIONS: The Ki67-decrease and the lower post-NACT Ki67 are independent factors associated with favorable RFS, indicating that they could be precise biomarker candidates for prognosis in NACT-administered patients with advanced ovarian cancer.


Subject(s)
Neoadjuvant Therapy , Ovarian Neoplasms , Chemotherapy, Adjuvant , Female , Humans , Ki-67 Antigen , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/pathology , Prognosis , Retrospective Studies
2.
Gynecol Minim Invasive Ther ; 7(1): 40-43, 2018.
Article in English | MEDLINE | ID: mdl-30254935

ABSTRACT

Ovarian epidermoid cyst, an extremely rare tumor occurring mostly in older females, is lined by mature stratified squamous epithelium and distinguishable from mature teratoma by the absence of skin adnexae and other tissues. In imaging, these tumors resemble solid tumors, necessitating most patients to undergo oophorectomy to verify malignancy. We herein present the case of an ovarian epidermoid cyst in a pregnant woman who underwent laparoscopic cystectomy after delivery with preserved ovarian function. To the best of our knowledge, this is the first case report of an ovarian epidermoid cyst that was detected during pregnancy and treated with laparoscopic cystectomy. Preservation of ovarian function and application of minimally invasive surgery should be strongly considered in young patients with ovarian epidermoid cysts.

3.
Food Funct ; 7(6): 2566-73, 2016 Jun 15.
Article in English | MEDLINE | ID: mdl-27080730

ABSTRACT

Proteins non-enzymatically react with reducing sugars to form advanced glycation end-products (AGEs), resulting in the induction of protein denaturation. Because the levels of AGE increase with age and are elevated in age-related diseases, such as diabetes and atherosclerosis, the intake of compound(s) that inhibit the formation of AGEs by daily meal may represent a potential strategy for preventing age-related diseases. In this study, we measured the inhibitory effects of several Eucommia ulmoides extracts on the formation of AGEs, N(ε)-(carboxymethyl)lysine (CML) and N(ω)-(carboxymethyl)arginine (CMA). Although a crude extract obtained from E. ulmoides bark is widely used as herbal medicine, E. ulmoides leaf extract (ELE) inhibited CML and CMA formation more effectively during the incubation of gelatin with ribose. Therefore, the inhibitory effects of compounds present in ELE on CML and CMA formation were studied. As a result, isoquercetin showed the strongest inhibitory effect of all the tested ELE components. These results indicate that the oral intake of ELE may inhibit the formation of AGEs, thereby ameliorating age-related diseases.


Subject(s)
Eucommiaceae/chemistry , Glycation End Products, Advanced/chemistry , Plant Extracts/pharmacology , Arginine/analogs & derivatives , Arginine/chemistry , Flavonoids/pharmacology , Fructose/chemistry , Galactose/chemistry , Gelatin/chemistry , Glucose/chemistry , Glycosides/pharmacology , Lysine/analogs & derivatives , Lysine/chemistry , Mannose/chemistry , Ribose/chemistry , Tandem Mass Spectrometry
SELECTION OF CITATIONS
SEARCH DETAIL